These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16096588)

  • 1. Patients with known or suspected lung cancer: evaluation of clinical management changes due to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) study.
    Pepe G; Rossetti C; Sironi S; Landoni C; Gianolli L; Pastorino U; Zannini P; Mezzetti M; Grimaldi A; Galli L; Messa C; Fazio F
    Nucl Med Commun; 2005 Sep; 26(9):831-7. PubMed ID: 16096588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
    Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
    Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
    Kubota K; Matsuno S; Morioka N; Adachi S; Koizumi M; Seto H; Kojo M; Nishioka S; Nishimura M; Yamamoto H
    Ann Nucl Med; 2015 Jun; 29(5):431-41. PubMed ID: 25812534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early clinical experience and impact of 18F-FDG PET.
    Gutte H; Højgaard L; Kjaer A
    Nucl Med Commun; 2005 Nov; 26(11):989-94. PubMed ID: 16208177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
    Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
    Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
    Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
    J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
    Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
    J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies.
    Kamel EM; McKee TA; Calcagni ML; Schmidt S; Markl S; Castaldo S; Delaloye AB
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):641-6. PubMed ID: 15726357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
    van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
    J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients.
    Santiago JF; Gonen M; Yeung H; Macapinlac H; Larson S
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):61-7. PubMed ID: 16557205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of PET on the management of lung cancer: the referring physician's perspective.
    Seltzer MA; Yap CS; Silverman DH; Meta J; Schiepers C; Phelps ME; Gambhir SS; Rao J; Valk PE; Czernin J
    J Nucl Med; 2002 Jun; 43(6):752-6. PubMed ID: 12050318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer.
    Zhao DS; Valdivia AY; Li Y; Blaufox MD
    Semin Nucl Med; 2002 Oct; 32(4):272-5. PubMed ID: 12524651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer.
    Chang MC; Chen JH; Liang JA; Lin CC; Yang KT; Cheng KY; Yeh JJ; Kao CH
    Acad Radiol; 2012 Mar; 19(3):349-57. PubMed ID: 22173321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of 18F-FDG PET in evaluating cancers of lung.
    Acker MR; Burrell SC
    J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective.
    Meta J; Seltzer M; Schiepers C; Silverman DH; Ariannejad M; Gambhir SS; Phelps ME; Valk P; Czernin J
    J Nucl Med; 2001 Apr; 42(4):586-90. PubMed ID: 11337546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the addition of the brain region to the FDG-PET/CT imaging area in patients with suspected or diagnosed lung cancer.
    Tasdemir B; Urakci Z; Dostbil Z; Unal K; Simsek FS; Teke F; Goya C
    Radiol Med; 2016 Mar; 121(3):218-24. PubMed ID: 26541882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.